This weight reduction effect, one of the salient merits of GLP-1 receptor agonists, appeared slightly inferior to that of weekly subcutaneous semaglutide (4.11 kg
So, while GLP-1 compounders have technically been operating to fill an availability void, theyve also been de facto solving for the price issue
A weight loss of at least 10% was achieved by 22.6% of patients in the twice-daily group, 17.4% in the once-daily group, and 9.7% in the placebo group
[14] [15] NICE guidance and local commissioning policies outline BMI thresholds, referral pathways, and duration criteria for these treatments within NHS services
Consider your tolerance for side effects
Catching things early is key